Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan.
A 74-year-old man was admitted with rhabdomyolysis after undergoing initial treatment for gastrointestinal cancer with irinotecan. The syndrome partially resolved after the discontinuation of all of his usual medications, including his chronic selective serotonin reuptake inhibitor (SSRI). The rhabdomyolysis was exacerbated upon reinitiation of the SSRI and disappeared when the SSRI was discontinued. The combination of irinotecan and SSRI resulted in potentially lethal rhabdomyolysis.
Richards
Sarah
S
Winship Cancer Center and the Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Umbreit
Jay N
JN
Fanucchi
Michael P
MP
Giblin
Joan
J
Khuri
Fadlo
F
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D002166:Camptothecin / Q000009:adverse effects* / Q000031:analogs & derivatives*; D015283:Citalopram / Q000009:adverse effects*; D003866:Depressive Disorder / Q000188:drug therapy; D004347:Drug Interactions; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006801:Humans; D000077146:Irinotecan; D008297:Male; D012206:Rhabdomyolysis / Q000139:chemically induced*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D000972:Antineoplastic Agents, Phytogenic; D002166:Camptothecin; D015283:Citalopram; D000077146:Irinotecan; D017367:Selective Serotonin Reuptake Inhibitors